Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 7, 2020

View Archived Issues

Tau keeps gliomas in check

AVETUX trial shows potential of avelumab and cetuximab with FOLFOX in colorectal cancer

Janssen Biotech describes new STING agonists

Cav3.2 blockers patented by Nippon Chemiphar and Kindai University

HEXAPharmatec discovers new catechol derivatives

Curis and Aurigene amend their collaboration agreement for CA-170

Positive update for phase I/IIa study of OpRegen in dry AMD

Karuna Therapeutics updates research and discovery efforts in CNS

Novan gives update on the phase III B-SIMPLE program of SB-206

Phase I data for magrolimab plus avelumab regimen in ovarian cancer

AVN-576 shows promise in rat models of TBI

Sino announces IND filing for TDI-01 for fibrosis

Phase I results for troriluzole plus nivolumab in patients advanced or refractory solid tumors

Pan-Cancer Project looks closer, sees more

Genentech describes new NLRP3 inflammasome inhibitors

Inhibition of HSP90A, a potential strategy to combat NANOG+ immune-refractory tumors

Low dose eRapa safe and well-tolerated in prostate cancer patients

Phase III trial of Fintepla in Lennox-Gastaut syndrome meets primary endpoint

Boehringer Ingelheim studies BI-905681 in phase I for advanced, unresectable or metastatic tumors

Adial initiates pivotal phase III trial of AD-04 for alcohol use disorder

Kleo obtains IND clearance to study KP-1237 in combination with NK cells for multiple myeloma

Betta Pharmaceuticals patents PD-1/PD-L1 interaction inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
New 5-HT2C receptor agonists reported in Hansoh patent
BioWorld Science
Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have disclosed tricyclic compounds acting as 5-HT2C receptor...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...